Trans1, medical device company developing products to treat spinal disease, filed terms Friday with the SEC for its upcoming IPO. The company plans to offer 5.5 million shares at a price range of $12 to $14 per share. Lehman Brothers and Piper Jaffray are the joint book runners on the deal.
